NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZITUVIMET XR (sitagliptin and metformin hydrochloride) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2024.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIMET XR is a fixed-dose combination of sitagliptin (a DPP-4 inhibitor) and metformin hydrochloride extended-release for oral use. It is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. The combination works by enhancing insulin secretion in response to glucose and reducing hepatic glucose production.
Growth
Early-stage product in growth phase with moderate competitive pressure (30/100), presenting opportunities for field building and market establishment teams.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Career Relevance
ZITUVIMET XR represents a growth-stage branded generic opportunity in a mature therapeutic category. Professionals joining this product team will focus on maximizing formulary coverage, driving primary care adoption, and defending market share against competitive generics—skills valuable for long-term diabetes franchise leadership.
Worked on ZITUVIMET XR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.